We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Review of methods for measuring β-cell function: Design considerations from the Restoring Insulin Secretion ( RISE) Consortium.
- Authors
Hannon, Tamara S.; Kahn, Steven E.; Utzschneider, Kristina M.; Buchanan, Thomas A.; Nadeau, Kristen J.; Zeitler, Philip S.; Ehrmann, David A.; Arslanian, Silva A.; Caprio, Sonia; Edelstein, Sharon L.; Savage, Peter J.; Mather, Kieren J.; for the RISE Consortium
- Abstract
The Restoring Insulin Secretion ( RISE) study was initiated to evaluate interventions to slow or reverse the progression of β-cell failure in type 2 diabetes ( T2D). To design the RISE study, we undertook an evaluation of methods for measurement of β-cell function and changes in β-cell function in response to interventions. In the present paper, we review approaches for measurement of β-cell function, focusing on methodologic and feasibility considerations. Methodologic considerations included: (1) the utility of each technique for evaluating key aspects of β-cell function (first- and second-phase insulin secretion, maximum insulin secretion, glucose sensitivity, incretin effects) and (2) tactics for incorporating a measurement of insulin sensitivity in order to adjust insulin secretion measures for insulin sensitivity appropriately. Of particular concern were the capacity to measure β-cell function accurately in those with poor function, as is seen in established T2D, and the capacity of each method for demonstrating treatment-induced changes in β-cell function. Feasibility considerations included: staff burden, including time and required methodological expertise; participant burden, including time and number of study visits; and ease of standardizing methods across a multicentre consortium. After this evaluation, we selected a 2-day measurement procedure, combining a 3-hour 75-g oral glucose tolerance test and a 2-stage hyperglycaemic clamp procedure, augmented with arginine.
- Subjects
CELL physiology; INSULIN; DISEASE progression; TYPE 2 diabetes; INCRETINS; DRUG efficacy; THERAPEUTICS
- Publication
Diabetes, Obesity & Metabolism, 2018, Vol 20, Issue 1, p14
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.13005